Review: Cooperative group trials — Southwest Oncology Group (SWOG) innovations in advanced prostate cancer

Tanya B. Dorff; David I. Quinn; Cathy M. Tangen; E. David Crawford; Daniel P. Petrylak; Celestia S. Higano; Derek Raghavan; Nicholas J. Vogelzang; Ian M. Thompson

doi:10.1177/1758834009343454

Review: Cooperative group trials — Southwest Oncology Group (SWOG) innovations in advanced prostate cancer

Tanya B. Dorff, David I. Quinn, Cathy M. Tangen, E. David Crawford, Daniel P. Petrylak, Celestia S. Higano, Derek Raghavan, Nicholas J. Vogelzang, Ian M. Thompson

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

The major goals of the Southwest oncology genitourinary (SWOG-GU) committee in the area of advanced prostate cancer are to improve the survival and quality of life (QOL) of patients with advanced prostate cancer. SWOG trials have examined the role of combined androgen blockade, intermittent androgen deprivation, and the early application of chemotherapy in castration-naïve disease. In addition, they have contributed to advancing the current chemotherapy standard of docetaxel plus prednisone, and ongoing trials seek to improve upon that standard. Finally, surrogate endpoints have been identified and markers of treatment response or resistance with novel technology are under active investigation. This review highlights findings from recent SWOG clinical trials for advanced prostate cancer, emphasizing the clinical impact and future applications of the data.

Original language	English (US)
Pages (from-to)	69-77
Number of pages	9
Journal	Therapeutic Advances in Medical Oncology
Volume	1
Issue number	2
DOIs	https://doi.org/10.1177/1758834009343454
State	Published - Sep 2009
Externally published	Yes

Keywords

advanced prostate cancer
androgen deprivation
chemotherapy
clinical trials

ASJC Scopus subject areas

Oncology

Access to Document

10.1177/1758834009343454

Cite this

@article{3ae3dd99c5fe4cdda84bb053bf025ac7,

title = "Review: Cooperative group trials — Southwest Oncology Group (SWOG) innovations in advanced prostate cancer",

abstract = "The major goals of the Southwest oncology genitourinary (SWOG-GU) committee in the area of advanced prostate cancer are to improve the survival and quality of life (QOL) of patients with advanced prostate cancer. SWOG trials have examined the role of combined androgen blockade, intermittent androgen deprivation, and the early application of chemotherapy in castration-na{\"i}ve disease. In addition, they have contributed to advancing the current chemotherapy standard of docetaxel plus prednisone, and ongoing trials seek to improve upon that standard. Finally, surrogate endpoints have been identified and markers of treatment response or resistance with novel technology are under active investigation. This review highlights findings from recent SWOG clinical trials for advanced prostate cancer, emphasizing the clinical impact and future applications of the data.",

keywords = "advanced prostate cancer, androgen deprivation, chemotherapy, clinical trials",

author = "Dorff, {Tanya B.} and Quinn, {David I.} and Tangen, {Cathy M.} and Crawford, {E. David} and Petrylak, {Daniel P.} and Higano, {Celestia S.} and Derek Raghavan and Vogelzang, {Nicholas J.} and Thompson, {Ian M.}",

year = "2009",

month = sep,

doi = "10.1177/1758834009343454",

language = "English (US)",

volume = "1",

pages = "69--77",

journal = "Therapeutic Advances in Medical Oncology",

issn = "1758-8340",

publisher = "SAGE Publications Inc.",

number = "2",

}

TY - JOUR

T1 - Review

T2 - Cooperative group trials — Southwest Oncology Group (SWOG) innovations in advanced prostate cancer

AU - Dorff, Tanya B.

AU - Quinn, David I.

AU - Tangen, Cathy M.

AU - Crawford, E. David

AU - Petrylak, Daniel P.

AU - Higano, Celestia S.

AU - Raghavan, Derek

AU - Vogelzang, Nicholas J.

AU - Thompson, Ian M.

PY - 2009/9

Y1 - 2009/9

N2 - The major goals of the Southwest oncology genitourinary (SWOG-GU) committee in the area of advanced prostate cancer are to improve the survival and quality of life (QOL) of patients with advanced prostate cancer. SWOG trials have examined the role of combined androgen blockade, intermittent androgen deprivation, and the early application of chemotherapy in castration-naïve disease. In addition, they have contributed to advancing the current chemotherapy standard of docetaxel plus prednisone, and ongoing trials seek to improve upon that standard. Finally, surrogate endpoints have been identified and markers of treatment response or resistance with novel technology are under active investigation. This review highlights findings from recent SWOG clinical trials for advanced prostate cancer, emphasizing the clinical impact and future applications of the data.

AB - The major goals of the Southwest oncology genitourinary (SWOG-GU) committee in the area of advanced prostate cancer are to improve the survival and quality of life (QOL) of patients with advanced prostate cancer. SWOG trials have examined the role of combined androgen blockade, intermittent androgen deprivation, and the early application of chemotherapy in castration-naïve disease. In addition, they have contributed to advancing the current chemotherapy standard of docetaxel plus prednisone, and ongoing trials seek to improve upon that standard. Finally, surrogate endpoints have been identified and markers of treatment response or resistance with novel technology are under active investigation. This review highlights findings from recent SWOG clinical trials for advanced prostate cancer, emphasizing the clinical impact and future applications of the data.

KW - advanced prostate cancer

KW - androgen deprivation

KW - chemotherapy

KW - clinical trials

UR - http://www.scopus.com/inward/record.url?scp=77953443633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953443633&partnerID=8YFLogxK

U2 - 10.1177/1758834009343454

DO - 10.1177/1758834009343454

M3 - Review article

AN - SCOPUS:77953443633

SN - 1758-8340

VL - 1

SP - 69

EP - 77

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

IS - 2

ER -

Review: Cooperative group trials — Southwest Oncology Group (SWOG) innovations in advanced prostate cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this